Sacubitril-valsartan treatment for 3 months significantly decreased the respiratory event index from 20 to 7 events/h in patients with heart failure with reduced ejection fraction.
Cohort (n=18)
Open-label
No
Does sacubitril-valsartan reduce the respiratory event index in patients with HFrEF and central or obstructive apneas?
Sacubitril-valsartan therapy in patients with HFrEF is associated with a significant reduction in both central and obstructive sleep apneas, alongside improvements in cardiac function.
Absolute Event Rate: 7% vs 20%
p-value: p=0.003
OBJECTIVE: This study aimed to evaluate the effect of sacubitril-valsartan (SV) on central apneas (CA) and obstructive apneas (OA) in patients with heart failure with reduced ejection fraction (HFrEF). METHODS: In patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later. RESULTS: Of a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to 7 ± 7 events/h, p = 0.003). When subgrouping according to type of apneas, REI, and time spent below 90% saturation (T90) decreased in patients with CA and OA (all p < 0.05). CONCLUSION: In this prospective study, SV treatment for 3 months in patients with CA and OA is associated with a significant decrease in REI.
Wang et al. (2022) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=18). Sacubitril-valsartan vs. Baseline was evaluated on Respiratory event index (REI) (p=0.003). Sacubitril-valsartan treatment for 3 months significantly decreased the respiratory event index from 20 to 7 events/h in patients with heart failure with reduced ejection fraction.